期刊文献+

风湿清治疗类风湿关节炎的机制研究

原文传递
导出
摘要 目的:研究风湿清对类风湿性关节炎的作用机制。方法:58只大鼠均进行类风湿关节炎的建模,两组大鼠均在免疫后第14 d给药治疗,甲氨蝶呤片治疗的为对照组,风湿清治疗的为风湿清组,进行6周的治疗干预。结果:风湿清组与对照组大鼠治疗干预6周后,血RNAKL、MIP-1α以及IL-17水平风湿清组为31.6±2.2 pmol/L、273±25 pg/ml、10.6±0.5 ng/L,对照组为28.3±2.1 pmol/L、292±25pg/ml、12.6±1.3 ng/L,两组比较,均为P<0.05。结论:风湿清对类风湿关节炎的作用显著,可显著抑制RA-FLS分泌IL-17及TNF-α,调控RA-FLS的炎性增殖,进而保护骨组织,抑制骨破坏。
作者 欧大明 张济
出处 《中药药理与临床》 CAS CSCD 北大核心 2015年第2期149-149,共1页 Pharmacology and Clinics of Chinese Materia Medica
基金 一种传统经验方剂风湿清抗类风湿关节炎作用的机制研究 编号:14C0987
  • 相关文献

参考文献1

二级参考文献14

  • 1Mikuls T, Moreland L. Predicting outcomes in early rheumatoid arthritis [J]. Curr Rheumatol Rep, 2002, 4 : 193.
  • 2Singh P P, van der Kraan A G, Xu J, et al. Membrane- bound receptor activator of NF-κB ligand (RANKL) activity displayed by osteoblasts is differentially regulated by osteolytic factors[J]. Biochem Biophys Res Commun, 2012, 422 ( 1 ):48.
  • 3Rooney T, Edwards CK 3rd, Gogarty M, et al. Synovial tissue rank ligand expression and radiographic progression in rheumatoid arthritis: observations from a proof-of-concept randomized clinical trial of cytokine blockade[J]. Rheumatol Int, 2010, 30(12) : 1571.
  • 4Scott D L. Prognostic factors in early rheumatoid arthritis[J]. Rheumatology ( Oxford), 2000, 39 ( suppl 1): 24.
  • 5Ju J H, Cho M L, Jhun J Y, et al. Oral administration of type-Ⅱ collagen suppresses IL-17-associated RANKL expression of CD^4+ T cells in collagen-induced arthritis [J]. Immunol Lett, 2008,117 ( 1 ) : 16.
  • 6Kotake S, Yago T, Kawamoto M, et al. Role of osteoclasts and interleukin-17 in the pathogenesis of rheumatoid arthritis: crucial 'human osteoclastology' [J]. J Bone Miner Metab, 2012, 30(2) :125.
  • 7Sato K, Suematsu A, Okamoto K, et al. IL-17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction [J]. J Exp Med, 2006, 203(12) : 2673.
  • 8O' Gradaigh D, Ireland D, Bord S, et al. Joint erosion in rheumatoid arthritis: interactions between tumour necrosis factor alpha, interleukin 1, and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclasts [J]. Ann Rheum Dis, 2004, 63 (4) :354.
  • 9Schett G, Middleton S, Bolon B, et al. Additive bone-protective effects of anabolic treatment when used in conjunction with RANKL and tumor necrosis factor inhibition in two rat arthritis models [ J ]. Arthritis Rheum, 2005, 52(5):1604.
  • 10Goldring M B, Marcu K B. Cartilage homeostasis in health and rheumatic diseases [ J ]. Arthritis Res Ther, 2009,11 (3) :224.

共引文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部